Remdesivir-003-S, identified by the CAS number 946565-74-8, is a nucleotide analog with antiviral properties, primarily developed for the treatment of viral infections, including COVID-19. As a prodrug, it is metabolized in the body to its active form, which inhibits viral RNA polymerase, thereby disrupting viral replication. The compound exhibits a broad spectrum of activity against various RNA viruses, making it a valuable therapeutic option in managing viral outbreaks. In terms of its chemical characteristics, Remdesivir-003-S is typically characterized by its molecular structure, which includes a modified adenosine backbone, contributing to its mechanism of action. The substance is usually administered intravenously, and its pharmacokinetics involve rapid distribution and metabolism, with a focus on achieving effective concentrations in target tissues. Safety and efficacy profiles are continuously evaluated in clinical settings, and it is essential to monitor for potential side effects, as with any antiviral therapy. Overall, Remdesivir-003-S represents a significant advancement in antiviral drug development, particularly in response to emerging viral threats.

Remdesivir-003-S

946565-74-8: Remdesivir-003-S, identified by the CAS number 946565-74-8, is a nucleotide analog with antiviral properties, primarily developed for the treatment of viral infections, including COVID-19. As a prodrug, it is metabolized in the body to its active form, which inhibits viral RNA polymerase, thereby disrupting viral replication. The compound exhibits a broad spectrum of activity against various RNA viruses, making it a valuable therapeutic option in managing viral outbreaks. In terms of its chemical characteristics, Remdesivir-003-S is typically characterized by its molecular structure, which includes a modified adenosine backbone, contributing to its mechanism of action. The substance is usually administered intravenously, and its pharmacokinetics involve rapid distribution and metabolism, with a focus on achieving effective concentrations in target tissues. Safety and efficacy profiles are continuously evaluated in clinical settings, and it is essential to monitor for potential side effects, as with any antiviral therapy. Overall, Remdesivir-003-S represents a significant advancement in antiviral drug development, particularly in response to emerging viral threats.

CAS 946565-74-8

Remdesivir-003-S

Remdesivir Impurity 16

Ref: ST-EA-CP-R40019